Isis sees way to Phase III with triglyceride lowerer
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals has released positive Phase II data for an investigational treatment, ISIS-APOCIII, for the ultra-orphan disease, familial chylomicronemia syndrome (FCS).